<p><strong>EGFR Mutation-Positive, Metastatic Non-Small Cell Lung Cancer</strong>: Afatinib is indicated for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have non-resistant epidermal growth factor receptor (EGFR) mutations as detected by an FDA-approved test.<br />
<br />
<strong>Limitation of Use</strong>: The safety and efficacy of Afatinib have not been established in patients whose tumors have resistant EGFR mutations.<br />
<br />
<strong>Previously Treated, Metastatic Squamous NSCLC</strong>: Afatinib is indicated for the treatment of patients with metastatic squamous NSCLC progressing after platinum-based chemotherapy.</p>